Richly valued stocks with price-to-sales ratios greater than 10 times can leave investors holding the bag when stocks bubbles pop, says Kailash Concepts Research. Read More...
Motley Fool
Why Shares of Amarin Corporation Dropped 46.1% in May
Amarin Corporation (NASDAQ: AMRN), a biopharmaceutical company that specializes in cardiovascular therapies, saw its shares plummet 46.1% in May, according to data from S&P Global Market Intelligence. The company has only one marketed therapy, Vascepa (icosapent ethyl), which is designed to reduce the risk of stroke or heart attack by lowering harmful triglycerides, a type of fat in your blood. The problem for Amarin is that Vascepa now has three generic competitors compared to only one at this time last year.
Add Comment